Navigation Links
University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis

AURORA, Colo. (PRWEB) January 16, 2013

Cancer researchers are increasingly aware that in addition to genetic mutations in a cancer itself, characteristics of the surrounding tissue can promote or suppress tumor growth. One of these important tissue characteristics is inflammation – most cancers prosper in and attach to inflamed tissue and so many cancers have developed ways to create it.

A University of Colorado Cancer Center study published today in the Journal of Clinical Investigation shows that the protein SPARC (Secreted Protein Acidic and Rich in Cysteine) acts much like an anti-inflammatory drug, attempting to heal tissues inflamed by tumors. Likewise, cancers – for example, bladder cancer in this study – have developed ways to turn off the production of SPARC, thus allowing growth and metastasis, especially to the lung where bladder cancer is frequently fatal.

"In fact, we show the effects of SPARC go beyond even this anti-inflammatory role. Additionally, the protein is involved in disallowing migrating cancer cells from attaching at possible metastasis sites and stopping the production of new blood vessels needed to feed tumor tissue," says Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center and the study's senior author.

The study started by evaluating SPARC levels in human bladder cancer samples. In less aggressive cancers, both the tumor and the surrounding tissue made SPARC. In more aggressive cancers, it was just the surrounding tissue that made SPARC – the aggressive tumor itself had suppressed production of the protein. In these human bladder cancer tumors, more SPARC was associated with longer survival.

This distinction between SPARC made in the tumor and SPARC made in the surrounding tissue largely explains previous work that found high SPARC in aggressive tumors and so suggested a possible tumor-promoting role for the protein. Instead, it seems that surrounding healthy tissue may respond to a growing tumor by increasing SPARC production, which it hopes will mute the tumor. Thus high SPARC that is in fact an attempt at tumor suppression can be coincidentally associated with aggressive tumors when the entire tumor is examined.

Healthy tissue turns up SPARC to mute tumors. Aggressive cancers turn down SPARC to promote tumors.

Then Theodorescu and colleagues turned to animal models without the ability to manufacture SPARC. Not only was bladder cancer quicker to develop in these models, but the cancer was also more likely to travel to invade lung tissue. When SPARC was added to these models, tumor growth and metastasis was reduced.

"This is a comprehensive portrait of SPARC function using human and murine bladder cancer as a model, and the first to clearly distinguish between the role of SPARC generated in the tumor and the role of the protein generated in the surrounding tissue," says Theodorescu. "We hope this provides the rational basis for further exploring manipulation of SPARC as a therapeutic intervention."


This study was supported in part by NIH grant CA143971

The CU Cancer Center is headquartered on the University of Colorado Anschutz Medical Campus and is a consortium of three state universities (Colorado State University, University of Colorado Boulder and University of Colorado Denver) and six health delivery institutions: University of Colorado Health System (including University of Colorado Hospital, Poudre Valley Hospital and Medical Center of the Rockies), Children’s Hospital Colorado, Denver Health, Denver VA Medical Center, National Jewish Health and Kaiser Permanente Colorado.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Rice University discovers that graphene oxide soaks up radioactive waste
2. Carin Grings remains identified by researchers at Uppsala University
3. Nanonex Delivered Advanced Nanoimprint Tool NX-B200 to Swinburne University of Technology, Australia
4. University of Pennsylvania Purchases Nanonex Advanced Nanoimprint Tool NX-2600 BA
5. Eqalix Enters Sponsored Research Agreement with Temple University
6. Bed Bugs Find Their Way to University of Washington and Hastings-on-Hudson Libraries; Bed Bug Control 911 Advises Use of Bed Bug Spray to Effectively Clear the Pests Away
7. University of College London Hospitals (UCLH) Selects GEO SCAN Medical as New Standard of Care for the Detection and Treatment of Prostate Cancer
8. iLab Solutions Core Facility Management Software Named a University Business Magazine 2012 Readers’ Choice Top Product
9. Ben-Gurion University awarded $6.5 million grant to develop nano thin infrared night vision glasses
10. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
11. Moscow State University Hospital Selects Ekahau RTLS to Improve Operations and Patient Safety
Post Your Comments:
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
Breaking Biology News(10 mins):